Pharma channel feed

Seat­tle's AGC plots $194M in­vest­ment to dou­ble pro­duc­tion at Copen­hagen site in busy year for bi­o­log­ics

5 years ago
Outsourcing
Coronavirus

#ASH20 saw a BC­MA brawl. Who's still stand­ing? And who got knocked out for good?

5 years ago
R&D

Zio­phar­m's ac­tivist dra­ma con­tin­ues as an­oth­er board mem­ber mem­ber re­signs. Is the end in sight?

5 years ago

BioCryst wins ap­proval for HAE pill and charges half-a-mil­lion dol­lars, but will any­one take it?

5 years ago
FDA+

Mer­ck sells off its Mod­er­na stake af­ter mak­ing record gains amid the pan­dem­ic

5 years ago

Roche turns up the heat on Lil­ly with an­oth­er Gavre­to ap­proval, el­bow­ing its way in­to the thy­roid can­cer space

5 years ago
FDA+

Long af­ter Mer­ck and Bris­tol My­ers cre­at­ed a multi­bil­lion-dol­lar mar­ket, the PD-1 lead­ers are once again duk­ing it out — this time over a $12B-plus pot

5 years ago
R&D

Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

5 years ago
Cell/Gene Tx

Not so fast, Mr Pres­i­dent: Trump's plan for low­er­ing pre­scrip­tion drug prices hits a road­block, as Cana­da bans bulk drug ex­ports

5 years ago
People

Zio­pharm and a mi­nor­i­ty in­vestor spent Thanks­giv­ing fight­ing over con­trol of the com­pa­ny as ac­tivist at­tack con­tin­ues to un­fold

5 years ago

Shop­ping for a hol­i­day pipeline gift? How about an an­ti-NGF an­ti­body from Astel­las?

5 years ago

Bax­ter con­tin­ues on-shoring push with $50M In­di­ana ex­pan­sion

5 years ago
Outsourcing

Eu­ro­pean Union aims to es­tab­lish patent workaround in case of emer­gen­cies while try­ing to strength­en its own IP

5 years ago

Pur­due Phar­ma pleads guilty in fed­er­al Oxy­Con­tin probe, for­mal­ly rec­og­niz­ing it played a part in the opi­oid cri­sis

5 years ago

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

5 years ago

Roche tacks on an­oth­er Xofluza in­di­ca­tion as flu sea­son meets pan­dem­ic

5 years ago
FDA+

A poll sug­gests vac­cine da­ta boost­ed Pfiz­er's pub­lic im­age, but oth­er da­ta point to long road ahead

5 years ago
Coronavirus

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

5 years ago
FDA+

With on­ly weeks left in his pres­i­den­cy, Trump makes a fi­nal, long-shot bid to re­make US drug pric­ing

5 years ago

J&J joins Bris­tol My­ers Squibb with $100M com­mit­ment to di­ver­si­ty ef­forts

5 years ago

Phar­ma lob­by­ist and long­time Biden loy­al­ist Steve Ric­chet­ti joins the in­ner cir­cle head­ed to the White House as drug pric­ing re­mains a hot top­ic

5 years ago
People

An­a­lysts poured cold wa­ter, but FDA gives a fast-pass for Sanofi's new Pompe dis­ease drug

5 years ago
FDA+

Bris­tol My­ers Squibb Foun­da­tion launch­es pro­gram to tack­le di­ver­si­ty prob­lem in clin­i­cal tri­als

5 years ago
R&D

Retrophin no more: Shkre­li's lega­cy dis­ap­pears as for­mer com­pa­ny be­comes Tra­vere Ther­a­peu­tics

5 years ago
People
First page Previous page 252253254255256257258 Next page Last page
A service from the Financial Times